Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg dose-frequency crossover trial in CIDP
NL-OMON41611Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of kiovig in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change from baseline in hand grip strength. Started Apr 2015; status: active, not recruiting.
02
Drugs
kiovig
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON41611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41611.